- Home
- MEGI vs FTRE Comparison
MEGI vs FTRE Comparison
Compare MEGI & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGI
- FTRE
- Stock Information
- Founded
- MEGI 2021
- FTRE 1996
- Country
- MEGI United States
- FTRE United States
- Employees
- MEGI N/A
- FTRE N/A
- Industry
- MEGI Investment Managers
- FTRE Medical Specialities
- Sector
- MEGI Finance
- FTRE Health Care
- Exchange
- MEGI Nasdaq
- FTRE Nasdaq
- Market Cap
- MEGI 749.0M
- FTRE 701.9M
- IPO Year
- MEGI N/A
- FTRE N/A
- Fundamental
- Price
- MEGI $14.53
- FTRE $10.11
- Analyst Decision
- MEGI
- FTRE Hold
- Analyst Count
- MEGI 0
- FTRE 9
- Target Price
- MEGI N/A
- FTRE $12.06
- AVG Volume (30 Days)
- MEGI 178.0K
- FTRE 1.9M
- Earning Date
- MEGI 01-01-0001
- FTRE 11-07-2025
- Dividend Yield
- MEGI 11.40%
- FTRE N/A
- EPS Growth
- MEGI N/A
- FTRE N/A
- EPS
- MEGI N/A
- FTRE N/A
- Revenue
- MEGI N/A
- FTRE $2,733,500,000.00
- Revenue This Year
- MEGI N/A
- FTRE N/A
- Revenue Next Year
- MEGI N/A
- FTRE N/A
- P/E Ratio
- MEGI N/A
- FTRE N/A
- Revenue Growth
- MEGI N/A
- FTRE N/A
- 52 Week Low
- MEGI $10.63
- FTRE $3.97
- 52 Week High
- MEGI $14.89
- FTRE $25.28
- Technical
- Relative Strength Index (RSI)
- MEGI 58.98
- FTRE 62.03
- Support Level
- MEGI $14.26
- FTRE $9.42
- Resistance Level
- MEGI $14.58
- FTRE $10.57
- Average True Range (ATR)
- MEGI 0.15
- FTRE 0.65
- MACD
- MEGI 0.00
- FTRE -0.06
- Stochastic Oscillator
- MEGI 78.05
- FTRE 50.27
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.